We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Two plus two equals more

11 June 2008 By Martin Hutchinson

Daiichi Sankyo’s purchase of control in Ranbaxy is a great deal for both. Ranbaxy’s founding family gets a hefty premium for an overleveraged company, while Daiichi gets Ranbaxy’s cheap, high quality manufacturing to help it attack the opening Japanese generic drug market.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)